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Background
In this module, you will learn about the principles of treating latent TB infection (LTBI) and TB disease. A 
person with LTBI is treated to prevent them from progressing to TB disease. Some people with LTBI are at 
very high risk of developing TB disease, and they should receive high priority for LTBI treatment. Patients 
with LTBI who do not complete treatment as prescribed can develop TB disease. 
TB disease is treated to cure the patient and to stop the spread of TB. As a health care worker, you may 
be responsible for ensuring that TB patients take their medications as prescribed. This is very important 
because patients with TB disease who do not complete treatment as prescribed may become infectious 
and spread TB to others or develop drug-resistant TB. 
This module also explains the possible side effects of the drugs used to treat LTBI and TB disease. If you 
work with TB patients, it is important to be aware of the signs and symptoms of these side effects.
Note: The Self-Study Modules on Tuberculosis are a series of educational modules designed to provide information about TB in a self-
study format. The target audiences include outreach workers, nurses, physicians, administrators, health educators, and students from 
a variety of settings.  The Modules should not be used as a substitute for guidelines and should not be used for patient care decisions.  
Objectives define
explain
list
describe
After working through this module,  you will be able to
1. List the groups of people who should receive high 
priority for LTBI treatment.
2. Describe treatment regimens for LTBI.
3. Describe treatment regimens for TB disease.
4. Describe the principles of preventing drug resistance.
5. Describe patient monitoring during LTBI and TB 
disease treatment.
6. Describe TB treatment adherence strategies.
7. List the common adverse reactions to the drugs used 
to treat LTBI and TB disease.
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Doctor reviewing a chest x-ray.
New Terms
New terms introduced in this module are included below. These terms appear in bold in the module text.
adherence to treatment—following the recommended 
course of treatment by taking all the prescribed 
medications for the entire recommended time
adverse reaction—negative side effect resulting from the 
use of a drug (for example, hepatitis, nausea, headache)
antiretroviral therapy (ART)—a lifelong combination drug 
treatment to suppress HIV and improve the quality and 
length of life for a person living with HIV/AIDS
case management—a strategy health departments can 
use to manage patient care and help ensure patients 
successfully complete treatment
clinical evaluation—an evaluation done to find out 
whether a patient has symptoms or signs of TB disease or 
is responding to treatment; also done to check for adverse 
reactions to TB medications
continuation phase—the period after the first 8 weeks of 
TB disease treatment, during which tubercle bacilli that 
remain after the intensive phase are treated with at least 
two drugs
daily regimen—a treatment schedule in which the patient 
takes a dose of each prescribed medication every day
directly observed therapy (DOT)—a strategy devised 
to help patients adhere to treatment; a designated 
person watches the TB patient swallow each dose of the 
prescribed drugs to ensure adherence to and tolerability 
of the regimen
electronic directly observed therapy (eDOT)—DOT that 
is delivered remotely (e.g., over a smartphone, tablet, or 
computer). eDOT can either be real-time or recorded.
ethambutol (EMB)—a drug used to treat TB disease; 
may cause vision problems. Ethambutol should be used 
cautiously in children who are too young to be monitored 
for changes in their vision.
extensively drug-resistant TB (XDR TB)—a type of 
MDR TB that is resistant to isoniazid and rifampin, plus 
resistant to any fluoroquinolone and at least one of three 
injectable anti-TB drugs (such as amikacin, kanamycin, or 
capreomycin)
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hepatitis—inflammation of the liver, causing symptoms 
such as nausea, vomiting, abdominal pain, fatigue, and 
brown urine; hepatitis can be caused by several drugs 
used to treat LTBI or TB disease
intensive phase—the first 8 weeks of TB disease 
treatment, during which most of the tubercle bacilli  
are killed
intermittent therapy—a treatment schedule in which the 
patient takes each prescribed medication one, two, or 
three times weekly at the appropriate dosage
isoniazid (INH)—a drug that is used for treating LTBI 
and TB disease; although cheap and relatively safe, it 
may cause hepatitis and other adverse reactions in 
some patients
liver function tests—tests done to detect injury to the 
liver, such as hepatitis
LTBI treatment—medication that is given to people who 
have latent TB infection to prevent developing TB disease
multidrug-resistant TB (MDR TB)—TB that is resistant to 
at least the drugs isoniazid and rifampin; MDR TB is more 
difficult to treat than drug-susceptible TB
peripheral neuropathy—damage to the sensory nerves of 
the hands and feet, causing tingling, numbness, or pain in 
the hands and feet
pyrazinamide (PZA)—first-line drug for the treatment of TB 
disease, may cause hepatitis and other adverse reactions in 
some patients
pyridoxine—another name for vitamin B6; it is given to 
prevent peripheral neuropathy; should always be given to 
pregnant and breastfeeding women on isoniazid; and to 
patients with diabetes or HIV
rifabutin—a drug used to treat TB disease; used as a 
substitute for rifampin (RIF) in the treatment of all forms of TB 
rifampin (RIF)—a key drug used to treat TB disease; also used 
for LTBI treatment. Rifampin has several possible side effects 
(for example, hepatitis, turning body fluids orange, drug-
drug interactions, and flu-like symptoms).
rifapentine (RPT)—a drug used to treat TB disease; also used 
in the 12-dose regimen to treat LTBI
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MODULE
Treatment of Latent TB Infection (LTBI)
Why is LTBI treated?
LTBI is treated with medication to prevent the development of TB disease. Treatment of LTBI is essential 
for controlling and eliminating TB disease in the United States. 
LTBI is treated with medication to prevent the development of TB disease.
It is estimated that up to 13 million people in the United States have LTBI. While not everyone with LTBI 
will develop TB disease, about 5–10% of infected people will develop TB disease if not treated. 
Who should be tested for LTBI?
Some groups of people are at higher risk for TB than others (see Module 2, Epidemiology of Tuberculosis). 
These groups can be divided into two categories:
zz People who are at higher risk for exposure to or infection with M. tuberculosis
zz People who are at higher risk for developing TB disease once infected with M. tuberculosis
People in these groups should be identified through contact investigations or targeted testing 
programs. People who are diagnosed with LTBI with a positive tuberculin skin test (TST) or blood test 
(interferon-gamma release assay [IGRA]) should receive high priority for treatment of LTBI. Before starting 
LTBI treatment, it is very important to exclude TB disease.
People in certain groups should receive high priority for LTBI  
treatment  if they have a positive TST or IGRA result.
Before starting LTBI treatment, it is very important to exclude TB disease.
The criteria for determining who should receive high priority for LTBI treatment are listed in the  
following table (Table 4.1).
People without any risk factors should generally not be tested for TB infection. Testing should be 
targeted to groups at high risk for LTBI and TB disease (see Module 3, Targeted Testing and the Diagnosis 
of Latent Tuberculosis Infection and Tuberculosis Disease). However, if a person without any risk factors is 
tested and has a positive IGRA result or a TST reaction that is 15 mm or more, they should be evaluated 
for LTBI treatment. 
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A provider sharing materials.
Table 4.1 – High-Priority Candidates for LTBI Treatment Using a TST or IGRA.
People in these groups should be given high 
priority for LTBI treatment if they have a 
positive IGRA result or a TST reaction that is  
5 or more millimeters
People in these groups should be given high 
priority for LTBI treatment if they have a 
positive IGRA result or a TST reaction that is  
10 or more millimeters
• Recent contacts of people with infectious  
TB disease
• People living with HIV
• People with chest x-ray findings suggestive  
of previous TB disease
• Patients with organ transplants
• Other immunosuppressed patients (for 
example, patients on prolonged therapy  
with corticosteroids equivalent to/greater 
than 15 mg per day of prednisone for one 
month or more or those taking TNF-alpha 
antagonists)
• People born in countries where TB disease  
is common
• People who abuse drugs
• People who live or work in high-risk congregate 
settings (for example, nursing homes, 
correctional facilities, homeless shelters, 
hospitals, or other health care facilities)
• People who work in mycobacteriology 
laboratories
• People with medical conditions that increase 
the risk for TB disease (for example, silicosis, 
diabetes mellitus, severe kidney disease, 
certain types of cancer, and certain intestinal 
conditions)
• Children younger than 5 years of age
• Infants, children, and adolescents exposed to 
adults in high-risk groups
See Module 3, Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease, for information on 
interpreting a TST or IGRA result. In certain circumstances, people may be given LTBI treatment even if they do not have a 
positive TST or IGRA result (see the Special Considerations for LTBI Treatment section in this Module). 
Before starting treatment for LTBI, patients should receive a medical evaluation to exclude TB disease.
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Patient Medical Evaluation
Patient Medical Evaluation
All persons being considered for LTBI treatment should receive a medical evaluation. One reason for this 
evaluation is to exclude TB disease. Treating TB disease with an LTBI treatment regimen can lead to drug 
resistance (see the Preventing Drug Resistance section in this Module). To rule out TB disease, clinicians 
should determine whether the patient has symptoms of TB disease and evaluate the patient with a chest 
x-ray. People who are diagnosed with TB disease based on symptoms of TB disease, sputum specimens 
positive for acid-fast bacilli, or chest x-ray findings suggestive of TB disease, should be given treatment for 
TB disease, not LTBI.
All persons being considered for LTBI treatment  
should receive a medical evaluation.
TB disease should be excluded before starting LTBI treatment.
It is also important to determine whether the patient has ever been treated for LTBI or TB disease. In 
general, people who have been adequately treated should not be treated again. Neither the TST nor 
IGRA can determine whether a patient has received treatment for LTBI or TB disease. This is because 
most people who have a positive TST or IGRA result will have a positive result for the rest of their lives, 
regardless of whether they have received treatment. Furthermore, there are currently not enough data 
on the ability of either test to detect re-infection after treatment for both LTBI and TB disease. Thus, 
some people may require re-treatment if they are at risk of becoming re-infected and progressing to TB 
disease. Persons who complete LTBI treatment should be given documentation of completion.
It is also important to determine whether the patient  
has ever been treated for LTBI or TB disease.
Another reason for the medical evaluation is to find out whether the patient has other medical problems 
that may complicate therapy or require more careful monitoring during therapy. These patients include:
zz People living with HIV
zz People with a history of liver disorder or disease
zz People who use alcohol regularly
zz Women who are pregnant or just had a baby (within 3 months of delivery)
zz People who are taking other medications that may increase the risk of hepatitis
For these patients, baseline laboratory liver function tests are recommended before starting  
LTBI treatment.
It is also important to find out if the patient has ever had any adverse reactions to drugs used for LTBI 
treatment or if they are currently on medications that may interact with LTBI treatment medications.
It is important to find out if the patient is on other medications  
or has any medical problems that may complicate therapy.
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Finally, conducting a medical evaluation provides the health care worker an opportunity to build and 
establish rapport with the patient. Health care workers should highlight the important aspects of 
treatment, such as: 
zz Benefits of treatment
zz Importance of adherence to treatment
zz Possible adverse reactions
zz Establishing a follow-up plan
Medical evaluation allows health care providers  
to build and establish rapport with patients.
Because of the interaction between TB and HIV, health care workers should also recommend that 
patients undergo HIV counseling and testing.
Health care workers should recommend  
that patients undergo HIV testing and counseling.
Regimens for LTBI Treatment
Four regimens are approved for the treatment of LTBI (Table 4.2). While all the regimens are effective, 
health care providers should prescribe shorter regimens when possible. Patients are more likely to 
complete shorter treatment regimens. For more detailed information on treating LTBI, please refer to 
the CDC Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection guidelines and Update 
of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium 
tuberculosis Infection, available from the CDC website (www.cdc.gov/tb).
Isoniazid and Rifapentine Regimen (12-Dose Regimen)
The 12-dose regimen is a combination of isoniazid (INH) and rifapentine (RPT) given in 12 once-a-week 
doses. The 12-dose regimen of INH and RPT is sometimes referred to as “3HP.”  The 12-dose regimen of 
INH and RPT can be given under directly observed therapy (DOT) or self-administered therapy (SAT). 
Health care providers should choose the mode of administration (DOT or SAT) based on local practice, 
individual patient attributes and preferences, and other considerations including risk of progression to 
severe forms of TB disease. 
The regimen is recommended for patients 2 years of age or older, including people with HIV/AIDS who 
are taking antiretroviral medications that have acceptable drug-drug interactions with rifapentine, such 
as efavirenz and raltegravir.    
The 12-dose regimen of isoniazid and rifapentine is recommended  
for people 2 years of age or older, including people with HIV/AIDS  
who are taking antiretroviral medications that have  
acceptable drug-drug interactions with rifapentine.
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The 12-dose regimen of isoniazid and rifapentine is NOT recommended for:
zz Children younger than 2 years of age,
zz People with HIV/AIDS who are taking antiretroviral medications with clinically significant or 
unknown drug interactions with once-weekly rifapentine,
zz People presumed to be infected with isoniazid or rifampin-resistant M. tuberculosis, and
zz Pregnant women or women expecting to become pregnant during the 12–week regimen.
Rifampin
Rifampin (RIF) is also recommended for people with a positive TST or IGRA result, especially if they 
have been exposed to isoniazid-resistant TB. LTBI treatment with rifampin should be given daily for 
4 months to both adults and children. Rifampin should not be used in HIV-infected persons being 
treated with some combinations of antiretroviral therapy (ART). In situations where rifampin cannot 
be used, sometimes another drug, rifabutin, may be substituted.
LTBI treatment with rifampin should be given daily for 4 months.
Isoniazid – 9 Month Regimen
Nine months of isoniazid for LTBI treatment is very effective in preventing the development of TB 
disease in both people infected with HIV and those not infected with HIV. 
Nine months of isoniazid for LTBI treatment is very effective  
in preventing the development of TB disease in both people  
infected with HIV and those not infected with HIV.
Isoniazid – 6 Month Regimen
Six months of isoniazid is another treatment option, and may be preferred by some clinicians from 
a cost-effectiveness standpoint and because some patients may find it easier to adhere to a shorter 
treatment regimen. However, it is important to note that 9 months of isoniazid is more effective than 
6 months.  
Since isoniazid for LTBI treatment is not always effective when it is given for less than 6 months, every 
effort must be made to ensure that patients receive it for at least 6 months. 
The 6-month treatment regimen is not recommended for people living with HIV, children, and 
people with chest x-ray findings suggestive of previous TB disease.
The 6-month isoniazid treatment regimen is not recommended  
for people living with HIV, children, and people with chest x-ray  
findings suggestive of previous TB disease.
Rifampin and Pyrazinamide
The previously used LTBI treatment regimen of rifampin and pyrazinamide (PZA) should no longer 
be used due to reports of severe liver injury and death.
The combination of rifampin and pyrazinamide should NOT be used.
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Table 4.2 – LTBI Treatment Regimens.
Drugs Duration Dose Frequency Total 
Doses
Comments
Isoniazid* 
and 
Rifapentine†
3 months
Adults and Children 12 
years of age and over:
Isoniazid: 15 mg/kg 
rounded up to the nearest 
50 or 100 mg; 900 mg 
maximum
Rifapentine:
10.0–14.0 kg 300 mg
14.1–25.0 kg 450 mg
25.1–32.0 kg 600 mg
32.1–49.9 kg 750 mg  
≥50.0 kg 900 mg maximum
Children aged 2–11 years:
Isoniazid: 25 mg/kg; 900 
mg maximum
Rifapentine: as above
Once  
weekly‡ 12
Not recommended for children 
younger than 2 years of age, 
HIV-infected patients taking 
antiretroviral medications with 
clinically significant or unknown 
drug interactions with once-
weekly rifapentine, patients with 
presumed isoniazid or rifampin 
resistant M. tuberculosis, pregnant 
women, or women expecting 
to become pregnant within the 
treatment period
DOT or SAT may be used
Rifampin§ 4 months
Adult: 10 mg/kg
Children: 15–20 mg/kgı
Maximum dose: 600 mg
Daily 120
Recommended for patients who 
have isoniazid-resistant, rifampin-
susceptible LTBI
Not recommended for  
HIV-infected patients on certain 
combinations of ART; rifabutin 
may be used instead
Isoniazid 9 months
Adult: 5 mg/kg
Children: 10-20 mg/kg¶
Maximum dose: 300 mg
Daily 270
The preferred isoniazid  
regimen is daily treatment  
for 9 months
DOT must be used with twice-
weekly dosing
Adult: 15 mg/kg
Children: 20-40 mg¶
Maximum dose: 900 mg
Twice  
weekly‡ 76
Isoniazid 6 months
Adult: 5 mg/kg
Children: Not  
recommended
Maximum dose: 300 mg
Daily 180
Not recommended for people 
with HIV, children, and  
people with chest x-ray findings 
suggestive of previous TB disease
DOT must be used with twice-
weekly dosing
Adult: 15 mg/kg
Children: Not 
recommended
Maximum dose: 900 mg
Twice  
weekly‡ 52
*Isoniazid is formulated as 100 mg and 300 mg tablets.
†Rifapentine is formulated as 150 mg tablets in blister packs that should be kept sealed until use.
‡Intermittent isoniazid regimens must be provided via directly observed therapy (DOT), that is, a health care worker observes 
the ingestion of medication. DOT or SAT may be used for the 12-dose regimen of isoniazid and rifapentine. 
§Rifampin (rifampicin; RIF) is formulated as 150 mg and 300 mg capsules.
ıThe American Academy of Pediatrics acknowledges that some experts use rifampin at 20–30 mg/kg for the daily regimen 
when prescribing for infants and toddlers (American Academy of Pediatrics. Tuberculosis. In: Kimberlin DW, Brady MT,  
Jackson MA, Long SS, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American  
Academy of Pediatrics; 2018:829–853).
¶The American Academy of Pediatrics recommends an isoniazid dosage of 10–15 mg/kg for the daily regimen and  
20–30 mg/kg for the twice-weekly regimen.
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Study Questions 4.1 – 4.4
4.1 Which statement is true about the purpose of LTBI treatment?
A. It is given to people who have LTBI to prevent them from testing positive on 
future tests for TB infection
B. It is given to people who have LTBI to prevent them from developing  
TB disease
C. It is given to people who have TB disease to prevent the disease from 
getting worse
D. It is given to people who have TB disease to prevent them from  
becoming infectious
4.2 Which groups of people should receive high priority for LTBI 
treatment if they have a positive IGRA result or a TST reaction with 
an induration that is 5 millimeters or larger? Name five.
4.3 Which groups of people should receive high priority for LTBI 
treatment if they have a positive IGRA result or a TST reaction with 
an induration that is 10 millimeters or larger? Name seven. 
4.4 List the four regimens that are approved for the treatment of LTBI.
Answers to study questions are on pages  43–50
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Special Considerations for LTBI Treatment
Directly Observed Therapy (DOT) 
DOT for LTBI treatment should be considered for persons who are at especially high risk for TB disease 
(e.g., young children) and are either taking an intermittent regimen or are suspected of nonadherence. 
DOT is a strategy used to help patients adhere to treatment. It means that a health care worker or another 
designated person watches the patient swallow each dose of the prescribed drugs to ensure adherence to 
and tolerability of the regimen. Because of the importance of each dose, DOT is recommended for patients 
on isoniazid regimens given twice weekly. For more information on DOT, see the Adherence to Treatment 
section of this module. 
DOT is a strategy used to help patients adhere to treatment.
Contacts
Contacts are people who have been exposed to someone with infectious TB disease. Contacts should be 
quickly identified, located, and assessed for TB disease and LTBI. If a contact’s TST or IGRA result is positive 
and TB disease is excluded, he or she should be considered high priority for LTBI treatment. If a contact’s 
TST or IGRA is negative, he or she should be retested if it has been less than 8 to 10 weeks after his or her 
last exposure to infectious TB disease. This is because it can take 2 to 8 weeks after being infected with  
M. tuberculosis for the body’s immune system to mount a response detectable by the tests. If the result of 
the repeat test is positive, and TB disease is excluded, the contact should be classified as recently infected 
and followed-up and treated appropriately. 
In general, contacts with a positive TST or IGRA and a documented history of completion of LTBI treatment 
do not need to be retreated. However, retreatment may be necessary for persons who are at high risk of 
becoming re-infected and progressing to TB disease (for example, immunocompromised persons). In 
complicated situations, a TB expert should be consulted.
Contacts at High Risk for Rapid Development of TB Disease
Sometimes LTBI treatment is given to people who have a negative TST or IGRA result. For example, some 
contacts at high risk for rapidly developing TB disease should start LTBI treatment even if they have a negative 
test and less than 8 to 10 weeks have passed since they were last exposed to TB. These contacts include
zz Children who are younger than 5 years of age (some TB programs may have different age  
cutoff guidelines)
zz People living with HIV
Some contacts may start taking LTBI treatment if they have a negative  
TST or IGRA result but less than 8 to 10 weeks have passed  
since they were last exposed to TB.
Once TB disease is ruled out, these contacts should start LTBI treatment to prevent them from rapidly 
developing TB disease. They also should be retested 8 to 10 weeks after they were last exposed to TB. If the 
contact has a positive TST or IGRA result, he or she should continue to take LTBI treatment. Contacts living 
with HIV may be given a full course of LTBI treatment even if their second TST or IGRA result is negative.
TB contacts living with HIV may be given a full course of  
LTBI treatment even if their second TST or IGRA result is negative.
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Expert consultation should be sought to determine if contacts with immunocompromised states 
other than HIV infection (e.g., contacts taking immunosuppressive therapies, diabetic patients) 
could benefit from treatment even if they have a negative TST or IGRA result. Offering treatment for 
presumed M. tuberculosis infection may be considered if the likelihood of infection is high, based on 
the circumstances of the exposure and prevalence of TB infection among other contacts.
Infants and Children 
Because of their age, infants and young children with a positive TST reaction must have been infected 
recently and are at high risk of rapidly developing TB disease. Infants and young children are also more 
likely than older children and adults to develop life-threatening forms of TB disease. 
Once TB disease has been ruled out, children who are younger than 5 years of age who have been 
exposed to TB should receive LTBI treatment, even if they have a negative TST result. This is because 
they are at high risk of rapidly developing TB disease and because they may have a false-negative TST 
reaction (see Module 3, Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis 
Disease). Because they are at high risk for rapidly developing TB disease, DOT should be considered for 
children taking LTBI treatment. Children should be retested 8 to 10 weeks after they were last exposed 
to TB.
Children who are younger than 5 years of age and who have been  
exposed to TB should start taking LTBI treatment,  
even if they have a negative TST result.
Children younger than 5 years of age should continue taking LTBI treatment until ALL of the following 
conditions are met:
zz The child is at least 6 months of age
zz The second TST is negative
zz The second TST was done at least 8 weeks after the child was last exposed to a person with 
infectious TB disease
The 12-dose regimen of isoniazid and rifapentine is not currently recommended for children younger 
than 2 years of age.
Contacts of Isoniazid-Resistant TB
If a person is a contact of a patient with isoniazid-resistant but rifampin-susceptible TB, a 4-month 
regimen of daily rifampin may be recommended. In situations where rifampin cannot be used, rifabutin 
may be substituted.
Contacts of Multidrug-Resistant TB
If a person is a contact of a patient with multidrug-resistant (MDR) TB, the risk for developing TB disease 
should be considered before recommending LTBI treatment. MDR TB contacts may be treated for 6 to 12 
months or they can be observed for signs and symptoms of disease without treatment.
If a person is a contact of a patient with MDR TB, the risk for developing  
TB disease should be considered before recommending LTBI treatment.
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If treating an MDR TB contact for LTBI, an alternative regimen of drugs to which the M. tuberculosis isolate 
is known to be susceptible should be used. Immunocompromised contacts (such as persons living 
with HIV) should be treated for 12 months. All persons with suspected MDR LTBI should be followed 
and observed for signs and symptoms of TB disease for 2 years, regardless of the treatment regimen. An 
expert in the treatment of MDR TB should also be consulted.
Pregnant Women
For most pregnant women with LTBI, treatment can be delayed until after delivery, even though 
isoniazid has NOT been shown to have harmful effects on the fetus. If the woman does not have any 
high risk factors for developing TB disease, treatment should be given after she has delivered her 
baby, so she can avoid having to take anti-TB medications during pregnancy. If the pregnant woman 
is a recent contact or is HIV-infected, immediate treatment should be considered. The preferred LTBI 
treatment regimen for pregnant women is 9 months of isoniazid with pyridoxine (vitamin B6). For 
women in the postpartum period (within 3 months of delivery), baseline liver function tests should  
be conducted.
Pregnant women should not be given LTBI treatment  
until after delivery, unless they have certain medical conditions.
The 12-dose regimen of isoniazid and rifapentine is not currently recommended for pregnant women or 
women expecting to be pregnant during the treatment regimen. 
Breastfeeding Women
Breastfeeding is not contraindicated for women taking isoniazid or rifampin. The amount of isoniazid 
or rifampin found in the breast milk is not harmful to the infant. Additionally, the concentration of 
drugs found in the breast milk is not considered effective treatment for the infant. Breastfeeding 
women who are taking isoniazid must be given a vitamin B6 supplement. Women who are taking 
rifampin may notice a normal orange discoloration of body fluids, including breast milk. 
Currently, there is not enough data to indicate whether the 12-dose regimen of isoniazid and 
rifapentine is safe for women to take while breastfeeding. 
People with HIV Infection
The 12-dose regimen of isoniazid and rifapentine is recommended for people with HIV infection 
who are taking antiretroviral medications that have acceptable drug-drug interactions with 
rifapentine, such as efavirenz and raltegravir. The 12-dose regimen of isoniazid and rifapentine is not 
recommended for people with HIV infection who are taking antiretroviral medications with clinically 
significant or unknown drug interactions with rifapentine.
People with HIV infection can also be treated with a 9-month regimen of isoniazid. For people  
with HIV infection who cannot tolerate isoniazid or who have been exposed to isoniazid-resistant  
M. tuberculosis, an alternative treatment is 4 months of rifampin. However, rifampin should not be used 
for people with HIV who are being treated with certain combinations of ART. In these cases, dose-
adjusted rifabutin may be given.
As new research occurs, guidelines may change. Expert consultation should be sought for the care 
and treatment of HIV-infected persons who have LTBI.
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Study Questions 4.5 – 4.8
4.5 What LTBI treatment regimen may be recommended for people with 
a positive TST or IGRA result who have been exposed to isoniazid-
resistant TB? Select one.
A. Isoniazid and rifapentine once a week for 12 weeks 
B. Rifampin daily for 4 months
C. Rifapentine once a week for 6 months
D. Ethambutol daily for 6 months
4.6 In what circumstances may LTBI treatment be given to people who 
have a negative TST or IGRA result? 
4.7 What conditions must be met to stop LTBI treatment for children 
who are 5 years old or younger and have been exposed to TB?
4.8 When should pregnant women be treated for LTBI and for how long?
Answers to study questions are on pages  43–50
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Case Study 4.1
You are sent to visit the home of a TB patient who was admitted 
to the hospital last week and diagnosed with infectious TB 
disease. Living in the home are his wife and his 1-year-old 
daughter. Neither one has symptoms of TB disease. You give 
them both a tuberculin skin test and return 2 days later to read 
the results. You find that the wife has 14 mm of induration, but 
the daughter has no induration.
z Should either one receive further evaluation for LTBI or TB disease? 
Should either one start LTBI treatment?  Explain.
Answers to case study questions are on pages 51–54
Adverse Reactions and Patient Monitoring
Adverse Reactions
Many health care providers have concerns about treating patients for LTBI. These concerns are generally 
related to the length of treatment and adverse reactions, or negative side effects. As many as 10% to 20% 
of people treated with isoniazid will have some mild, abnormal liver function tests results (tests done 
to detect injury to the liver) during treatment. In most people, these test results return to normal even 
when isoniazid treatment is continued. As with any treatment, the risks and benefits must be weighed 
for each individual. For example, isoniazid may cause hepatitis, or inflammation of the liver. Hepatitis 
prevents the liver from functioning normally, causing symptoms such as:
zz Nausea
zz Vomiting
zz Abdominal pain
zz Fatigue
zz Brown urine (patients taking rifampin or rifapentine will notice a different and normal orange-red 
discoloration of body fluids, including urine and tears). 
A risk of isoniazid and rifampin is hepatitis (inflammation of the liver).
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Isoniazid can cause hepatitis in anyone; however, hepatitis occurs in less than 1% of people taking 
isoniazid. Many things can cause hepatitis, including various viruses and other medications. There are 
certain risk factors that increase the risk of serious isoniazid hepatitis, such as alcoholism and older age. 
Although rare, there have been some cases of severe and fatal hepatitis. 
Some factors, such as older age and alcoholism,  
increase the risk that isoniazid will cause serious hepatitis.
Isoniazid can also damage the sensory nerves of the hands and feet. This is called peripheral 
neuropathy. The main symptom of peripheral neuropathy is a tingling sensation, a weakened sense of 
touch, or pain in the hands, palms, soles, and feet. Some conditions, such as HIV, alcoholism, diabetes, 
and malnutrition increase the risk for peripheral neuropathy. People with these conditions should be 
given vitamin B6.
Isoniazid can damage the sensory nerves of the hands and feet.
Patients taking either rifampin, rifapentine, or rifabutin should also be aware of possible adverse effects. 
Some infrequent side effects from these drugs can include:
zz Rash
zz Gastrointestinal symptoms (nausea, anorexia, and abdominal pain)
zz Orange discoloration of body fluids (e.g., urine, saliva, tears, or breast milk); soft contact lenses 
may be permanently stained 
zz Interaction with many other drugs, such as birth control pills and implants, warfarin, some HIV 
drugs, and methadone 
zz Hypersensitivity
Rifapentine may also cause flu-like symptoms.
Rifabutin may cause:
zz Eye inflammation
zz Joint pain
zz Lower white blood cell count 
All persons taking LTBI treatment should be educated  
about the symptoms caused by adverse reactions.
Patient Monitoring
All persons receiving LTBI treatment should be evaluated at least monthly during therapy for:
zz Adherence to the prescribed regimen 
zz Signs and symptoms of TB disease 
zz Adverse reactions (such as signs and symptoms of hepatitis) 
All persons receiving LTBI treatment should be evaluated  
at least monthly during therapy for signs 
 and symptoms of TB disease and adverse reactions.
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During each  monthly evaluation, patients should be asked whether they have nausea, abdominal pain, 
or any of the other symptoms that may be caused by adverse reactions. In addition, health care workers 
should examine patients for signs of these adverse reactions. Patients should be instructed to stop taking 
medications and contact their health care provider immediately if they have any signs or symptoms of 
hepatitis (Table 4.4) or other severe adverse reactions.
In general, baseline laboratory testing is not recommended unless the person is at high risk for hepatitis. 
People at greatest risk for hepatitis should have baseline liver function tests before starting LTBI treatment 
and during therapy. This includes:
zz People living with HIV 
zz People with a history of liver disorder or disease
zz People who drink alcohol regularly
zz Women who are pregnant or just had a baby (within 3 months of delivery)
zz People who are taking other medications that may increase the risk of hepatitis
People at greatest risk for hepatitis should have liver function tests 
 before starting isoniazid or rifampin and every month during therapy.
For all patients, isoniazid, rifampin, or rifapentine should be stopped if the results of liver function tests 
are three times higher than the upper limit of the normal range and the patient has symptoms, or if the 
results are five times higher than the upper limit of the normal range and the patient is asymptomatic. 
Expert consultation should be sought for difficult cases.
Treatment Follow-up
Patients should receive documentation of TST or IGRA results, regimens, and treatment completion 
dates. The patient should be told to present this document any time they are required to be tested 
for TB. Patients should also be re-educated about the signs and symptoms of TB disease. For detailed 
information on the treatment of LTBI, please refer to the CDC Targeted Tuberculin Testing and Treatment 
of Latent Tuberculosis Infection guidelines and Update of Recommendations for Use of Once-Weekly 
Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection, available from the 
CDC website (www.cdc.gov/tb).
All patients should receive documentation  
upon completion of LTBI treatment.
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Study Questions 4.9 – 4.13
4.9 Name four reasons why patients should receive a medical 
evaluation before starting LTBI treatment.
4.10 Why is it important to exclude the possibility of TB disease before 
giving a patient LTBI treatment?
4.11 Which of the following are symptoms of hepatitis? Select the 
correct answer(s).
A. Nausea
B. Weight gain
C. Vomiting 
D. Brown urine 
4.12 Who is at greatest risk for hepatitis? What special precautions 
should be taken for these patients?
4.13 How often should patients be evaluated for signs and 
symptoms of adverse reactions during LTBI treatment?   
Answers to study questions are on pages  43–50
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Case Study 4.2
A 65-year-old man is prescribed LTBI treatment with isoniazid 
because he is a contact of a person with infectious TB and he 
has an induration of 20 mm to the tuberculin skin test. His 
baseline liver function tests are normal, but he drinks a six-pack 
of beer every day. 
z What kind of monitoring is necessary for this patient while he is 
taking isoniazid?
Answers to case study questions are on pages 51–54
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4
MODULE
Treatment of TB Disease
Treating TB disease benefits both the person who has TB and the community. It helps the patient 
because it prevents disability and death and restores health; it benefits the community because it 
prevents the further transmission of TB.
TB disease must be treated for at least 6 months; in some cases, treatment lasts longer. Most of the 
actively multiplying tubercle bacilli are killed during the first 8 weeks of treatment (the intensive phase). 
However, some bacilli survive longer. Therefore, treatment with at least two drugs must be continued for 
several more months to kill or control these remaining bacilli (the continuation phase). If treatment is 
not continued for a long enough time, the surviving bacilli may cause TB disease in the patient at a later 
time (relapse). 
TB disease must be treated for at least 6 months;  
in some cases, treatment lasts longer.
TB treatment regimens must contain multiple drugs to which the organisms are susceptible. Treatment 
with a single drug can lead to the development of drug-resistant TB. The intensive phase for treating 
drug-susceptible TB disease should include the following four drugs (Figure 4.1):  
zz Isoniazid (INH)
zz Rifampin (RIF)
zz Pyrazinamide (PZA)
zz Ethambutol (EMB)
TB disease must be treated with multiple drugs  
to which the bacilli are susceptible.
The intensive phase for treating drug-susceptible TB disease should  
include four drugs: isoniazid, rifampin, pyrazinamide, and ethambutol.
When the drug susceptibility results are available, clinicians may change the regimen accordingly.  
For detailed information on the treatment of TB, please refer to the Official American Thoracic  
Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice 
Guidelines: Treatment of Drug-Susceptible Tuberculosis, available from the CDC website  
(www.cdc.gov/tb).
Module 4— Treatment of Latent Tuberculosis Infection and Tuberculosis Disease
21
Preventing Drug Resistance
Drug resistance can develop when patients are prescribed an inappropriate regimen for treatment. TB 
disease must be treated with multiple drugs to which the bacilli are susceptible. Using only one drug to 
treat TB disease can select a population of tubercle bacilli resistant to that drug. When multiple drugs are 
used together, each drug helps prevent the emergence of bacilli that are resistant to the other drugs. 
When a patient is not improving in response to a prescribed regimen, adding a single drug to that 
regimen may have the same effect as using only one drug for treatment: it can lead to drug resistance. 
Drug resistance can also develop when patients do not follow treatment regimens as prescribed — in 
other words, if they do not take all of their pills or they do not take their pills as often as prescribed. When 
this happens, the patients may expose the bacilli to a single drug.
Drug resistance can develop when patients are prescribed  
an inappropriate regimen for treatment or when patients 
 do not follow treatment regimens as prescribed.
Following are factors that increase the chance of a patient having or developing drug-resistant TB: 
zz Patient does not take their medicine regularly and completely
zz Patient comes from an area of the world where drug-resistant TB is common
zz Malabsorption of drugs
zz Patient is a contact to someone with drug-resistant TB
zz Failure to improve on drug-susceptible regimen 
zz Patient develops TB disease again after having taken TB medicine in the past
For more information on the development of drug-resistant TB, see Module 1, Transmission and 
Pathogenesis of Tuberculosis.
Treatment Regimens
The recommended treatment regimens are described in Table 4.3. This table is provided for you to use 
as a reference. For detailed information on TB treatment, please refer to the Official American Thoracic 
Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice 
Guidelines: Treatment of Drug-Susceptible Tuberculosis available from the CDC website (www.cdc.gov/tb).
Figure 4.1 Example of pills used to treat TB disease. From left to right: isoniazid, 
rifampin, pyrazinamide, and ethambutol.
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Table 4.3 – Drug Regimens for Pulmonary TB Caused by Drug Susceptible Organisms in Adults.*
Regimen Intensive 
Phase  
Drugs1
Intensive 
Phase Interval 
and Doses2
(minimum 
duration)
Continuation 
Phase  
Drugs
Continuation Phase  
Interval and Doses2,3
(minimum duration)
Range of total doses
(Intensive and 
Continuation phases, 
combined)
Comments3, 4 Regimen  
effectiveness
1 INH
RIF
PZA
EMB
7 days/week 
for 56 doses 
(8 weeks)
or
5 days/week 
for 40 doses 
(8 weeks)
INH
RIF 7 days/week for 126 doses (18 
weeks)
   or
5 days/week for 90 
doses (18 weeks)
182 to 130 This is the preferred 
regimen for patients 
with newly diagnosed 
pulmonary TB.
    greater
lesser
2 INH
RIF
PZA
EMB
7 days/week 
for 56 doses  
(8 weeks)
 or
5 days/week 
for 40 doses 
(8 weeks)
INH
RIF
3 times weekly 
for 54 doses (18 
weeks)
110 to 94 Preferred alternative 
regimen in situations in 
which more frequent 
DOT during continuation 
phase is difficult to 
achieve.
3 INH
RIF
PZA
EMB
3 times 
weekly for 24 
doses 
(8 weeks)
INH
RIF
3 times weekly 
for 54 doses (18 
weeks)
78 Use regimen with caution 
in patients with HIV 
and/or cavitary disease. 
Missed doses can lead to 
treatment failure, relapse, 
and acquired drug 
resistance.
4 INH
RIF
PZA
EMB
7 days/week 
for 14 doses 
then twice 
weekly for  
12 doses5
INH
RIF
Twice weekly for 36 
doses  
(18 weeks)
62 Do not use twice-weekly 
regimens in HIV-infected 
patients or patients with 
smear positive and/or 
cavitary disease. If doses 
are missed then therapy 
is equivalent to once 
weekly, which is inferior.
INH = isoniazid   RIF = rifampin   PZA = pyrazinamide   EMB = ethambutol   
* For dosing information, refer to the Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of 
America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
1 Other combinations may be appropriate in certain circumstances; additional details are provided in the Official American Thoracic Society/
Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible 
Tuberculosis.
2 When DOT is used, drugs may be given 5 days per week and the necessary number of doses adjusted accordingly. Although there are no 
studies that compare 5 with 7 daily doses, extensive experience indicates this would be an effective practice. DOT should be used when drugs 
are administered less than 7 days per week.
3 Based on expert opinion, patients with cavitation on initial chest radiograph and positive cultures at completion of 2 months of therapy 
should receive a 7-month (31-week) continuation phase.
4 Pyridoxine (vitamin B6), 25–50 mg/day, is given with INH to all persons at risk of neuropathy (e.g., pregnant women; breastfeeding infants; 
persons with HIV; patients with diabetes, alcoholism, malnutrition, or chronic renal failure; or patients with advanced age). For patients with 
peripheral neuropathy, experts recommend increasing pyridoxine dose to 100 mg/day.
5 Alternatively, some U.S. TB control programs have administered intensive-phase regimens 5 days per week for 15 doses (3 weeks), then twice 
weekly for 12 doses.
Note: Use of once-weekly therapy with INH 900 mg and rifapentine 600 mg in the continuation phase is not generally recommended. In 
uncommon situations where more than once-weekly DOT is difficult to achieve, once-weekly continuation phase therapy with INH 900 mg 
plus rifapentine 600 mg may be considered for use only in HIV uninfected persons without cavitation on chest radiography.
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Study Questions 4.14 – 4.17
4.14 Why must TB disease be treated for at least 6 months?
4.15 Which drugs are recommended for the intensive phase of 
treatment for TB disease? Select the correct answer(s).
A. Isoniazid (INH)
B. Rifapentine (RPT)
C. Rifampin (RIF)
D. Pyrazinamide (PZA)
E. Ethambutol (EMB)
4.16 Why should multiple drugs be used to treat TB disease?
4.17 What factors can lead to drug resistance? Select the correct 
answer(s).
A. The patient is prescribed an inappropriate treatment regimen
B. The patient does not follow the treatment regimen as prescribed
C. The patient follows an appropriate treatment regimen
D. Malabsorption of TB drugs
Answers to study questions are on pages 43–50
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Special Considerations
People Living with HIV  
For HIV-infected TB patients receiving antiretroviral therapy (ART), the recommended treatment of drug-
susceptible TB disease is a 6-month daily regimen consisting of:
zz An intensive phase of isoniazid, rifampin, pyrazinamide, and ethambutol for 2 months
zz A continuation phase of isoniazid and rifampin for 4 months.
The management of HIV-infected TB patients can be complex and therefore expert consultation should  
be sought for the care and treatment of these patients and to discuss alternative treatment regimens  
if necessary. 
To improve treatment outcomes for HIV-infected TB patients, ART should be initiated during TB treatment. 
For patients with CD4 cell counts less than 50/mm3, ART should ideally be initiated within the first 2 weeks 
of TB treatment. For patients with CD4 cell counts greater than or equal to 50/mm3, ART should ideally 
be initiated by 8 to 12 weeks of TB treatment. However, for HIV-infected patients with TB meningitis or TB 
involving the central nervous system, ART should NOT be initiated during the first 8 weeks of TB treatment. 
Additionally, it is important to be aware of the interaction of rifampin with some ART drugs. Rifabutin has 
fewer drug interaction problems and may be used as a substitute for rifampin in some situations.
If an HIV-infected patient is NOT receiving ART during TB treatment, it is recommended to prolong the 
patient’s treatment to 9 months (the continuation phase can be extended to 7 months).
DOT and other adherence promoting strategies should be used in all HIV-infected TB patients. The use of 
intermittent TB treatment regimens has been associated with high rates of relapse and the development 
of drug-resistance and therefore it is recommended that TB treatment be given daily in both the intensive 
and continuation phase for HIV-infected TB patients. As with all patients, HIV-infected TB patients should be 
closely monitored for their response to treatment.
HIV-infected TB patients should be closely monitored  
for their response to treatment.
If any patient does not seem to be responding to treatment, the patient should be reevaluated and the 
continuation phase can be increased to 7 months (a total of 9 months of treatment) if necessary. Because 
of the potential for drug-drug interactions, side effects, immune reconstitution inflammatory syndrome 
(worsening of TB symptoms), and the possibility of TB treatment failure or relapse, expert consultation 
should always be sought when treating HIV-infected TB patients.  
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Pregnant Women
Treatment should not be delayed for pregnant women who have TB disease; rather, it should begin 
as soon as TB is diagnosed. The treatment regimen should consist of at least isoniazid, rifampin, and 
ethambutol. Adding pyrazinamide to the treatment regimen for pregnant women is controversial in 
the United States. Therefore, expert consultation should be sought to evaluate the risks and benefits 
of prescribing pyrazinamide on a case-by-case basis. If pyrazinamide is not included in the treatment 
regimen, treatment should last for at least 9 months. Streptomycin, a second-line TB drug, should NOT 
be used because it has been shown to have harmful effects on the fetus. Vitamin B6 supplementation is 
recommended for all pregnant women who are taking isoniazid.
Treatment for pregnant women who have TB disease  
should begin as soon as TB is diagnosed.
Breastfeeding
Women being treated with the first-line TB drugs should not be discouraged from breastfeeding. Only 
a small concentration of the drugs is found in the breast milk and it is not harmful to the infant. The 
concentration of drugs found in breast milk is not considered effective treatment for LTBI or TB disease for 
the nursing infant. Vitamin B6 supplementation is recommended for all women who are taking isoniazid 
and are breastfeeding.
Children and Adolescents
TB treatment in infants and children younger than 5 years of age should be started as soon as the 
diagnosis is suspected. As with adults, it is recommended that children be treated for 6 months.
TB treatment in infants and children younger than 5 years  
of age should be started as soon as the diagnosis is suspected.
Children can be treated with the preferred four-drug regimen (isoniazid, rifampin, pyrazinamide, and 
ethambutol) for 2 months followed by a two-drug (isoniazid and rifampin) regimen for 4 months. 
However, children receiving ethambutol should be monitored for vision changes. Some clinicians use a 
three-drug regimen (isoniazid, rifampin, and pyrazinamide) in the intensive phase for children who are 
too young to have their vision monitored, who are not infected with HIV, have no prior TB treatment 
history, and are not at risk for having drug-resistant TB. When possible, it is preferred to treat children daily. 
However, children who are not infected with HIV may be treated two or three times a week during the 
continuation phase. Expert consultation should be sought if needed. Pills given to children may have to 
be crushed or given in a liquid form. 
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People with Extrapulmonary TB
In general, regimens that are used for treating pulmonary TB are also effective for treating extrapulmonary 
TB. Thus, 6 months of treatment is recommended for treating TB involving any site with the exception 
of the meninges or central nervous system, for which a 9 to 12-month regimen is recommended, or 
bone and joint TB, for which a 6 to 9 month regimen is recommended. Extending treatment should be 
considered for patients with TB in any site that is slow to respond.
Alternative Regimens for Treating Drug-Resistant TB
Alternative regimens should be used for treating drug-resistant TB. The treatment of drug-resistant TB 
should always be done with expert consultation from a physician who is familiar with the treatment of 
drug-resistant TB.
The treatment of drug-resistant TB should always be done  
with expert consultation from a physician who is familiar  
with the treatment of drug-resistant TB.
People with Isoniazid-Resistant TB
Isoniazid-resistant TB can be treated with the recommended 6-month, three-drug regimen (rifampin, 
ethambutol, and pyrazinamide).
People with TB Resistant to Isoniazid and Rifampin (MDR TB) 
It is more difficult to treat MDR TB than it is to treat drug-susceptible TB. More drugs are required to treat 
MDR TB, and these drugs are less effective and more likely to cause adverse reactions. When TB is resistant 
to isoniazid and rifampin, treatment is usually for 18 to 24 months after culture conversion. As a last resort, 
some patients with MDR TB may undergo surgery to remove part of the infected site. 
When TB is resistant to isoniazid and rifampin,  
treatment can last 2 years or longer.
People with Extensively Drug-Resistant TB (XDR TB) 
Extensively drug-resistant TB (XDR TB) is a rare type of MDR TB. XDR TB is defined as TB that is resistant to 
isoniazid and rifampin, plus any fluoroquinolone and at least one of three injectable anti-TB drugs (such as 
amikacin, kanamycin, or capreomycin).
Because XDR TB is resistant to first-line and second-line drugs, patients are left with less effective treatment 
options. XDR TB is difficult to treat and successful outcomes for the patient depend greatly on the extent of 
drug resistance, the severity of the disease, and whether the patient’s immune system is compromised.
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Study Questions 4.18 – 4.19
4.18 What treatment regimen should be used for HIV-infected TB patients?
4.1 In what situations should treatment for TB disease last longer than  
6 months?
Answers to study questions are on pages 43–50
Case Study 4.3
An 18-month-old girl is admitted to the hospital because of 
meningitis. Doctors discover that her grandmother had pulmonary 
TB and was treated with a 6-month regimen. The medical evaluation 
of the child confirms the diagnosis of TB meningitis.
z For how long should the child be treated? Why?
Answers to case study questions are on pages 51–54
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Treatment and Monitoring Plan
For each patient with newly diagnosed TB, a specific treatment and monitoring plan should be 
developed in collaboration with the local health department. This should be done within one week of 
the suspected diagnosis. This plan should include: 
zz A description of the treatment regimen
zz Methods of monitoring for adverse reactions
zz Methods of assessing and ensuring adherence to the treatment 
zz Methods for evaluating treatment response
Each TB patient should have a specific treatment and monitoring plan  
developed in collaboration with the local health department.
For detailed information on treating TB, refer to the Official American Thoracic Society/Centers for Disease 
Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-
Susceptible Tuberculosis, available from the CDC website (www.cdc.gov/tb).
Monitoring for Adverse Reactions
Before starting treatment, patients should have certain baseline blood and vision tests to help detect any 
problems that may complicate treatment. For example, patients who are taking ethambutol should have 
baseline visual acuity testing and testing of color discrimination. 
Before starting treatment, patients should have baseline tests  
to help detect any problems that may complicate treatment.
Follow-up tests should be done periodically if the results of the baseline tests indicate abnormalities or 
if the patient has symptoms that may be due to adverse reactions. For example, liver function tests and 
symptoms should be closely monitored for patients taking isoniazid who have pre-existing liver disease 
or patients who develop abnormal liver function. Patients taking ethambutol should have monthly color 
discrimination tests and be asked about vision changes. 
As with patients receiving LTBI treatment, all patients being treated for TB disease should be educated 
about the symptoms that are caused by adverse reactions to the drugs they are taking (Table 4.4). 
Patients should be warned about minor side effects such as nausea or orange-red discoloration of urine, 
as well as the symptoms of potentially serious side effects, such as vomiting, abdominal pain, or loss of 
appetite. Patients should be instructed to seek medical attention immediately if they have symptoms of 
a serious side effect.
All patients being treated for TB disease should be educated about  
the symptoms caused by adverse reactions to the drugs they are taking.
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All patients should be seen by a clinician at least monthly during treatment and evaluated for response 
and for possible adverse reactions. Monitoring for adverse reactions must be individualized, depending 
on the drugs the patient is taking and the patient’s risk for adverse reactions. 
All patients should be seen by a clinician at least monthly during  
treatment and evaluated for response and for possible adverse reactions.
During this evaluation, clinicians should ask patients whether they have any of the symptoms that may 
be due to adverse reactions and examine patients for signs of possible adverse reactions. Clinicians 
should also monitor patients for response to treatment. 
Public health workers who have regular contact with patients should ask patients about adverse 
reactions at every visit. If a patient has symptoms of a serious adverse reaction, the public health 
worker should:
zz Instruct the patient to stop the medication 
zz Report the situation to a clinician and arrange for a medical evaluation right away
zz Note the symptoms on the patient’s form
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Table 4.4 – Common Adverse Reactions to TB Drugs.
Caused by Adverse  Reaction Signs and Symptoms
Significance 
of Reaction*
Any drug Allergic • Skin rash May be serious or minor
Ethambutol Eye damage
• Blurred or changed vision
• Changed color vision
Serious
Pyrazinamide
Isoniazid
Rifampin
Hepatitis (liver 
toxicity)
• Abdominal pain
• Abnormal liver function test 
results
• Brown urine, light colored stool
• Fatigue
• Fever for 3 or more days
• Flu-like symptoms
• Lack of appetite
• Nausea
• Vomiting
• Yellow skin or eyes
Serious
Isoniazid
Nervous system 
damage
• Dizziness
• Tingling or numbness around 
the mouth
Serious
Peripheral  
neuropathy
• Tingling sensation, numbness, 
or pain in hands and feet Serious
Pyrazinamide
Stomach upset
• Stomach upset, vomiting, lack of 
appetite May be serious or minor
Gout
• Abnormal uric acid level
• Joint aches
Serious
Rifampin
Bleeding problems 
due to low platelets
• Easy bruising
• Slow blood clotting
Serious
Discoloration of 
body fluids
• Orange urine, sweat, or tears
• Permanently stained soft 
contact lenses
Minor
Drug interactions
• Interferes with many 
medications, such as birth 
control pills or implants, blood 
thinners, some HIV medicines, 
and methadone
May be serious or minor
*Patients should stop medication for serious adverse reactions and consult a clinician immediately. Patients can continue  
taking medication if they have minor adverse reactions.
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Study Questions 4.20 – 4.22
4.2 What should be included in each patient’s treatment plan? 
4.3 Name the drug(s) that may cause each of the following symptoms 
or adverse reactions.
zz Nervous system damage:
zz Hepatitis:
zz Eye damage:
zz Orange discoloration of the urine:
4.4 How often should patients be monitored for adverse reactions to 
TB drugs?
Answers to study  questions are on pages 43–50
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Case Study 4.4
You are assigned to deliver medications to TB patients as part of 
the DOT program where you work. When you visit Mr. Jackson’s 
house, you ask him how he is feeling. He tells you that he was up 
all night vomiting. 
z What are the possible causes? What should you do? 
Answers to case study questions are on pages 51–54
Case Study 4.5
Ms. Young, a patient who started treatment for TB disease last week, calls 
the TB clinic to complain that her urine has changed to an odd color. 
z Name two possible causes, and explain how each would affect the  
color of the urine.
Answers to case study questions are on pages 51–54
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Adherence to Treatment
Treatment for TB disease lasts longer and requires more drugs than treatment for most other infectious 
diseases. In order to cure TB and prevent drug resistance, patients with TB disease must follow the 
recommended course of treatment. This is called adhering to treatment. However, ensuring that patients 
adhere to treatment can be difficult because many patients are reluctant to take several different 
medications for many months.
In order to cure TB and prevent drug resistance,  
patients with TB must adhere to treatment.
There are many ways to encourage patients to adhere to treatment. The most effective strategy 
is directly observed therapy (DOT). DOT means that a health care worker or another designated 
person watches the TB patient swallow each dose of the prescribed drugs to ensure adherence to and 
tolerability of the regimen. This method of treatment should be considered for all patients because there 
is no way to reliably predict which patients will adhere to treatment. DOT should be done at a time and a 
place that are convenient for the patient. For example, health care workers can meet TB patients at work, 
at home, or in other locations to provide DOT. 
DOT should be considered for all patients because there is no way  
to reliably predict which patients will adhere to treatment.
Electronic DOT (eDOT) is an alternative method to in-person DOT in which a patient is remotely observed 
(e.g., over a smartphone, tablet, or computer) taking his or her TB medication. eDOT can be either real-time 
or recorded. During a real-time eDOT visit, the health care worker and the patient schedule a specific day and 
time to meet virtually, and the health care worker watches the patient take his or her medication. In contrast, 
recorded eDOT is when the health care worker and the patient do not set a specific time to meet, and the 
patient records himself or herself taking the medications. For more information on eDOT, please refer to 
Implementing an Electronic Directly Observed Therapy (eDOT) Program: A Toolkit for Tuberculosis (TB) Programs, 
available on the CDC website (www.cdc.gov/tb).
DOT should be used for all children and adolescents. Even when drugs are given under DOT, tolerance of the 
medications must be monitored closely. Parents should not be given the responsibility of supervising DOT. 
DOT is also highly recommended for patients on intermittent regimens (e.g., patients receiving treatment 
three times a week). Other persons who should be considered a high priority for receiving DOT include:
zz Patients with drug-resistant TB
zz Patients with positive sputum smears
zz Patients with delayed culture conversion
zz Patients with treatment failure or relapse
zz Patients with HIV infection
zz Persons at high risk for nonadherence, such as
z Homeless or persons with unstable housing
z Persons who abuse alcohol or use illicit drugs
z Persons who are unable to take pills on their own due to mental, emotional, or physical disabilities
z Children and adolescents
z Persons with a history of nonadherence
zz Residents at correctional or long-term care facilities
zz Patients who have been previously treated for TB disease or LTBI
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Another way to improve patient adherence is to offer incentives or enablers. Incentives are rewards given 
to patients to encourage them to take their own medicines or to keep their DOT or clinic appointments. 
For example, patients may be given food, restaurant coupons, clothing, or other items as an incentive. 
Enablers are things that help the patient receive treatment, such as bus tokens to get to the clinic. 
Incentives and enablers should be chosen according to the patient’s needs, and they are frequently 
offered along with DOT. 
Another way to improve patient adherence is to offer incentives or enablers.
An important part of helping patients take their medicine is to educate them about TB. This means talking 
to them about the cause of TB, the way TB is spread, the methods of diagnosing TB, and the specific 
treatment plan. 
Health care providers should take the time to clearly explain to patients when the medication should 
be taken, how much, and how often, especially if the patient is not receiving DOT. Written instructions 
should also be provided. Patients who understand these concepts are more likely to adhere to treatment. 
An important part of helping patients take their  
medicine is to educate them about TB. 
In summary, in order to prevent relapse and drug resistance, clinicians must prescribe an adequate 
regimen and make sure that patients adhere to treatment. For more information on treatment adherence, 
refer to Module 6, Managing Tuberculosis Patients and Promoting Adherence.
Monitoring Patients’ Adherence to Therapy
Patients who are not receiving DOT (i.e., self-administered therapy) should be monitored carefully for 
adherence to treatment. This can be done in at least four ways:
zz Check to see whether the patient is reporting to the clinic as scheduled, and ask the patient about 
adherence
zz Ask the patient to bring the prescribed medications to each clinic visit and count the number of 
pills to determine how many have been taken
zz Use special urine tests to detect the presence of the prescribed medication in the urine
zz Assess the patient’s clinical response to treatment 
Patients who are not receiving DOT should be  
monitored carefully for adherence to treatment.
None of these methods can be used to prove that a patient is taking every dose of the prescribed 
medication. The best way to ensure adherence to treatment is to use DOT.
The best way to ensure adherence to treatment is to use DOT. 
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Evaluating Patients’  Response to Treatment
Clinicians use three methods to determine whether a patient is responding to treatment. First, they can 
check to see whether the patient still has symptoms of TB (clinical evaluation). Although each patient 
responds to treatment at a different pace, most patients’  TB symptoms should gradually improve and 
eventually go away. Patients whose symptoms do not improve during the first 2 months of treatment, or 
whose symptoms worsen after improving initially, should be reevaluated.
Clinicians can evaluate a patient’s response to treatment  
by checking to see whether the patient still has symptoms of TB.
Patients whose symptoms do not improve during the first 2 months  
of treatment, or whose symptoms worsen after improving 
 initially, should be reevaluated.
Public health workers who have regular contact with patients should pay attention to improvement in 
symptoms. If a patient has worsening symptoms of TB or serious adverse reactions, the health worker 
should report the situation to the clinician, advise the patient to stop taking the medication, and arrange for 
a medical evaluation right away. The health worker should also note the symptoms on the patient’s forms. 
Second, clinicians can check a patient’s response to treatment by obtaining sputum or other specimens 
for acid fast bacilli (AFB) smear and culture. Specimens should be examined at least every month until 
the culture results have converted from positive to negative. Any patient whose culture results have not 
become negative after 2 months of treatment, or whose culture results become positive after being 
negative, should be carefully reevaluated for treatment failure, relapse, or acquired drug resistance.
Sputum specimens should be examined every month  
until the culture results have converted from positive to negative. 
Third, clinicians can use chest x-rays to monitor a patient’s response to treatment. Repeated chest x-rays are 
not as helpful as monthly bacteriologic and clinical evaluations. However, a chest x-ray taken at the end of 
treatment can be compared with any follow-up x-rays taken subsequently should symptoms recur. Chest 
x-rays are also useful for patients who have negative culture results before treatment. In these patients, the 
bacteriological response may be difficult to assess, and the clinician may have to rely on the clinical and 
x-ray responses.
Patients should have a chest x-ray at the end of treatment  
so that it can be compared with any chest x-rays given later on.
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The TST or IGRA cannot be used to determine whether a patient is responding to treatment. This is 
because the TST or IGRA measures the immune response to TB infection and, therefore, most people 
with a positive result will remain positive if they are tested later in their lives, regardless of whether they 
have received treatment.
The TST or IGRA cannot be used to determine  
whether a patient is responding to treatment.
Treatment completion is defined by the number of doses that a patient takes within a specific time 
frame. The length of therapy depends on the drugs used, the drug susceptibility test result, and the 
patient’s response to therapy.
Reevaluating Patients Who Do Not Respond to Treatment or Who Relapse 
Patients should be reevaluated promptly if: 
zz Symptoms do not improve during the first 2 months of therapy
zz Symptoms worsen after improving initially
zz Culture results have not become negative after 2 months of treatment
zz Culture results become positive after being negative
zz Chest x-rays show worsening
Reevaluating the patient means obtaining a new (sputum) specimen for TB culture and (if positive) for 
drug susceptibility testing, assessing whether the patient has been taking medication as prescribed, 
reviewing symptoms, performing a clinical examination, and repeating chest x-rays.
Any patient who has not responded to treatment after 2 months  
or who has relapsed should be reevaluated promptly.
The treatment of TB can be complicated, especially in patients who fail to respond to treatment, who 
relapse, have drug-resistant TB, or have serious adverse reactions to medications. A new regimen may 
be required, and treatment may last longer. Clinicians who do not have experience with these situations 
should consult a TB expert.
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Study Questions 4.23 – 4.27
4.5 Name four ways by which clinicians can assess whether a patient is 
adhering to treatment.
4.6 What is the best way to ensure that a patient adheres to treatment? 
4.7 How can clinicians determine whether a patient is responding to 
treatment? Select the correct answer(s).
A. Do bacteriologic evaluations 
B. Repeat tuberculin skin test
C. Do clinical evaluations 
D. Use special urine tests
4.8 Under what circumstances should patients be reevaluated?
4.9 What does reevaluating the patient mean?
Answers to study questions are on pages 43–50
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Case Study 4.6
Mr. Vigo was diagnosed with smear-positive pulmonary TB disease in 
January. He was treated with isoniazid, rifampin, and pyrazinamide 
by his private physician. He visited his physician again in March. 
His drug susceptibility test results were not available at the time 
of this appointment. Nevertheless, the physician discontinued his 
prescription of pyrazinamide and gave Mr. Vigo refills of isoniazid 
and rifampin. Mr. Vigo visited his physician again in April. He had a 
persistent cough, and his sputum smear was found to be positive.
z What should be done next?
Answers to case study questions are on pages 51–54
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What Is the Role of the Public Health Worker in TB Treatment?
Successful TB treatment is the responsibility of the medical providers and health care workers, not the patient. 
Public health workers in TB programs and other facilities play an important role in helping patients complete 
LTBI or TB treatment. 
A strategy that may be used to ensure patients complete TB treatment is case management. The strategy’s 
goal is to provide patient-centered care for completion of treatment and to ensure all public health activities 
related to stopping TB transmission are completed. Patient-centered care can help ensure successful 
treatment outcomes because it emphasizes tailoring treatment to address both the patient’s clinical and 
social concerns.
Case management is a strategy that can be used to  
ensure that patients complete TB treatment.
In case management, a health department employee is assigned responsibility for the management of 
specific patients. This person is held accountable for ensuring that each of their patients is educated about  
TB treatment and that their therapy is appropriate and continuous.
Many public health workers provide DOT, eDOT, or have regular contact with TB patients in clinics, 
nursing homes, drug treatment centers, or other facilities. At each visit with a patient, public health 
workers should look for signs and symptoms of adverse reactions to the medication. For this reason, 
public health workers must be familiar with the signs and symptoms of serious and minor adverse 
reactions to the drugs commonly used to treat TB. If a patient has symptoms of an adverse reaction, the 
public health worker should:  
zz Instruct the patient to stop the medication 
zz Report the situation to a clinician and arrange for a medical evaluation right away
zz Note the symptoms on the patient’s form 
At each visit with a TB patient, public health workers should  
look for signs and symptoms of adverse reactions to the medication.
Also, public health workers can help monitor a patient’s response to treatment for TB disease by looking for 
symptoms of TB disease. Patients receiving treatment for pulmonary TB disease usually have symptoms at 
the beginning of therapy, such as productive cough, fevers, heavy night sweats, weight loss, and sometimes 
chest pain or coughing up blood. These symptoms should gradually improve and eventually go away. At 
each visit with a patient, public health workers should pay attention to the patient’s improvement. 
Public health workers can help monitor a patient’s response to  
treatment for TB disease by looking for symptoms of TB disease.
In addition to providing DOT, public health workers may be responsible for locating patients who have 
missed DOT visits or clinic appointments and helping them return to treatment. They may also educate 
patients and their families about TB, serve as interpreters, arrange and provide transportation for patients, 
and refer patients to other social services as needed. Finally, in many areas public health workers work 
with physicians in private practice (physicians who do not work in the health department) to make sure 
that their TB patients complete an adequate regimen for TB treatment. For more information on case 
management, please refer to Module 6, Managing Tuberculosis Patients and Improving Adherence.
Module 4— Treatment of Latent Tuberculosis Infection and Tuberculosis Disease40
Study Questions 4.28 - 4.29
4.10 What is the goal of TB case management?
4.11 What should a public health worker do if he or she notices that a 
patient has symptoms of an adverse reaction?
Answers to study questions are on pages 43–50
Case Study 4.7
Ms. DeVonne began treatment for pulmonary TB disease 2 months ago, 
at the beginning of September. You have been supervising her eDOT. 
During the first few weeks of therapy, you noticed that Ms. DeVonne’s 
symptoms were improving a little. However, during an eDOT session in 
October, you see that Ms. DeVonne is coughing up blood, and she tells 
you that she feels like she has a fever.
z What should you do?
Answers to case study questions are on pages 51–54
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Answers to Study Questions
4.1 Which statement is true about the purpose of LTBI treatment? 
A. It is given to people who have LTBI to prevent them from testing positive on 
future tests for TB infection
B. It is given to people who have LTBI to prevent them from developing  
TB disease
C. It is given to people who have TB disease to prevent the disease from 
getting worse
D. It is given to people who have TB disease to prevent them from becoming 
infectious 
The correct answer is B. The purpose of LTBI treatment is to prevent people with 
LTBI from developing TB disease.
4.2 Which groups of people should receive high priority for LTBI 
treatment if they have a positive IGRA result or a TST reaction with 
an induration that is 5 millimeters or larger? Name five.
zz Recent contacts of people with infectious TB disease
zz People living with HIV
zz People with chest x-ray findings suggestive of previous TB disease 
zz Patients with organ transplants
zz Other immunosuppressed patients (for example, patients on prolonged 
therapy with corticosteroids equivalent to/greater than 15mg per day of 
prednisone or those taking TNF-alpha antagonists) 
4.3 Which groups of people should receive high priority for LTBI 
treatment if they have a positive IGRA result or TST reaction with an 
induration that is 10 millimeters or larger? Name seven. 
zz People who have come to the U.S. from areas of the world where TB is 
common (for example, Asia, Africa, Eastern Europe, Russia, or Latin America)
zz People who abuse drugs
zz People who live or work in high-risk congregate settings (for example, 
nursing homes, correctional facilities, homeless shelters, hospitals, or other 
health care facilities)
zz People who work in mycobacteriology laboratories
zz People with medical conditions that increase the risk for TB disease (for 
example, silicosis, diabetes mellitus, severe kidney disease, certain types of 
cancer, and certain intestinal conditions)
zz Children younger than 5 years of age
zz Infants, children, and adolescents exposed to adults in high-risk groups
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Answers to Study Questions (Continued)
4.4 List the four regimens that are approved for the treatment of LTBI.
zz Isoniazid and rifapentine once a week for 12 weeks
zz Rifampin for 4 months
zz Isoniazid for 9 months
zz Isoniazid for 6 months 
4.5 What LTBI treatment regimen may be recommended for people with 
a positive TST or IGRA result who have been exposed to isoniazid-
resistant TB? Select one.
A. Isoniazid and rifapentine once a week for 12 weeks
B. Rifampin daily for 4 months
C. Rifapentine once a week for 6 months
D. Ethambutol daily for 6 months
The correct answer is B. Treatment with rifampin for 4 months may be 
recommended in this situation.
4.6 In what circumstances may LTBI treatment be given to people who 
have a negative TST or IGRA result?  
Some contacts may start taking LTBI treatment even if they have a negative skin 
test and less than 8 to 10 weeks have passed since they were last exposed to TB. 
These contacts include
zz Children who are 5 years of age or younger (some TB programs may have 
different age cutoff guidelines)
zz People living with HIV 
Once TB disease is ruled out, these contacts should start LTBI treatment to 
prevent them from rapidly developing TB disease. They also should be retested 
8 to 10 weeks after they were last exposed to TB. If the contact has a positive TST 
or IGRA result, he or she should continue to take LTBI treatment. Contacts living 
with HIV may be given a full course of LTBI treatment even if their second TST or 
IGRA result is negative.
Expert consultation should be sought to determine if contacts with immune 
impairments other than HIV infection (e.g., contacts taking immunosuppressive 
therapies) could benefit from treatment even if they have a negative TST or 
IGRA result. Offering treatment for presumed M. tuberculosis infection may be 
considered if the likelihood of infection is high, based on the circumstances of 
the exposure and prevalence of TB infection among other contacts.
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Answers to Study Questions (Continued)
4.7 What conditions must be met to stop LTBI treatment for children who 
are 5 years old or younger and have been exposed to TB? 
Children 5 years and younger who have been exposed to TB should start taking 
LTBI treatment, even if they have a negative TST. Children should be retested 8 to 10 
weeks after they were last exposed to TB. LTBI treatment can be stopped if all of the 
following conditions are met:
zz The child is at least 6 months of age
zz The second TST is negative
zz The second TST was done at least 8 weeks after the child was last exposed to an 
adult with infectious TB disease
4.8 When should pregnant women be treated for LTBI and for how long? 
For most pregnant women with TB infection, LTBI treatment can be delayed until 
after delivery. If the pregnant woman is a recent contact or HIV-infected, immediate 
treatment should be considered. The preferred LTBI treatment regimen for pregnant 
women is 9 months of isoniazid with a vitamin B6 supplement.
4.9 Name four reasons why patients should receive a medical evaluation 
before starting LTBI treatment.  
All patients being considered for LTBI treatment should receive a medical evaluation 
in order to: 
zz Exclude the possibility of TB disease 
zz Determine whether they have ever been treated for TB infection or disease
zz Identify any medical problems that may complicate therapy or require more 
careful monitoring
zz Establish and build rapport with patient
4.10 Why is it important to exclude the possibility of TB disease before 
giving a patient LTBI treatment?  
It is important to exclude the possibility of TB disease because treating TB disease 
with a LTBI treatment regimen can lead to drug resistance.
4.11 Which of the following are symptoms of hepatitis?  Select the correct 
answer(s).
A. Nausea
B. Weight gain
C. Vomiting 
D. Brown urine  
The correct answers are A, C, and D. Symptoms of hepatitis include nausea, 
vomiting, and brown urine. Other symptoms include abdominal pain and fatigue.
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Answers to Study Questions (Continued)
4.12 Who is at greatest risk for hepatitis? What special precautions should  
be taken for these patients?  
The people at greatest risk for hepatitis are:
zz People living with HIV
zz People with a history of liver disorder or disease
zz People who drink alcohol regularly
zz Women who are pregnant or just had a baby (within the last 3 months)
zz People who are taking other medications that may increase the risk of hepatitis
These patients should have liver function tests before starting LTBI treatment,  
and during therapy. 
4.13 How often should patients be evaluated for signs and symptoms of 
adverse reactions during LTBI treatment?  
All persons receiving LTBI treatment should be evaluated at least monthly during 
therapy for signs and symptoms of adverse reactions. During each monthly evaluation, 
clinicians should ask patients whether they have nausea, abdominal pain, or any of the 
other symptoms that may be caused by adverse reactions. In addition, they should 
examine patients for signs of these adverse reactions.
4.14 Why must TB disease be treated for at least 6 months?  
TB disease must be treated for at least 6 months; in some cases, treatment lasts even 
longer. Most of the tubercle bacilli are killed during the first 8 weeks of treatment 
(the intensive phase). However, some bacilli survive. Therefore, treatment must be 
continued for several more months to kill or control these remaining bacilli (the 
continuation phase). If treatment is not continued for a long enough time, the surviving 
bacilli may cause TB disease in the patient at a later time (relapse).
4.15 Which drugs are recommended for the intensive phase of treatment for 
TB disease?  Select the correct answer(s).
A. Isoniazid (INH)
B. Rifapentine (RPT)
C. Rifampin (RIF)
D. Pyrazinamide (PZA)
E. Ethambutol (EMB)
The correct answers are A, C, D, and E. The intensive phase should include isoniazid 
(INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol (EMB). When the drug 
susceptibility results are available, clinicians may change the regimen accordingly. 
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Answers to Study Questions (Continued)
4.16 Why should multiple drugs be used to treat TB disease?  
Using only one drug to treat TB disease can select a population of tubercle bacilli 
that is resistant to that drug. When multiple drugs are used together, each drug 
helps prevent the emergence of bacilli that are resistant to the other drugs. 
4.17 What factors can lead to drug resistance? Select the correct answer(s).  
A. The patient is prescribed an inappropriate treatment regimen
B. The patient does not follow the treatment regimen as prescribed
C. The patient follows an appropriate treatment regimen
D. Malabsorption of TB drugs
The correct answers are A, B, and D. Drug resistance can develop when patients are 
prescribed an inappropriate regimen for treatment, when patients do not follow 
treatment regimens as prescribed, or malabsorption of TB drugs.
4.18 What treatment regimen should be used for HIV-infected TB patients?  
For HIV-infected TB patients receiving ART, the recommended treatment of drug-
susceptible TB disease is a 6-month daily regimen consisting of:
zz An intensive phase of isoniazid, rifampin, pyrazinamide, and ethambutol for  
2 months
zz A continuation phase of isoniazid and rifampin for 4 months
ART should be initiated during TB treatment. For patients with CD4 cell counts 
less than 50/mm3, ART should ideally be initiated within the first 2 weeks of TB 
treatment. For patients with CD4 cell counts greater than or equal to 50/mm3, ART 
should ideally be initiated by 8 to 12 weeks of TB treatment. However, for HIV-
infected patients with TB meningitis or TB involving the central nervous system, ART 
should NOT be initiated during the first 8 weeks of TB treatment. 
Additionally, it is important to be aware of the interaction of rifampin with some 
ART drugs. Rifabutin has fewer drug interaction problems and may be used as a 
substitute for rifampin in some situations.
DOT and other adherence promoting strategies should be used in all HIV-infected  
TB patients. 
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Answers to Study Questions (Continued)
4.19 In what situations should treatment for TB disease last longer than  
6 months? 
zz HIV-infected TB patients should receive a minimum of 6 months of treatment and 
be closely monitored for their response to treatment. If an HIV-infected patient is 
NOT receiving ART during TB treatment, it is recommended to prolong the patient’s 
treatment to 9 months (the continuation phase can be extended to 7 months). 
Also, as with any patient, if they do not seem to be responding to treatment, they 
should be reevaluated and the continuation phase can be increased to 7 months 
(a total of 9 months of treatment) if necessary.
zz Pregnant women with TB disease should receive at least 9 months of treatment
zz Persons with TB disease of the meninges or central nervous system should receive 
a 9 to 12-month regimen
zz Persons with bone or joint TB disease should receive a 6 to 9-month regimen
zz Extending treatment should be considered for patients with TB disease in any site 
that is slow to respond
zz Treatment for multidrug-resistant TB disease can last 18 to 24 months
4.20 What should be included in each patient’s treatment plan?  
This plan should include: 
zz A description of the treatment regimen
zz Methods of monitoring for adverse reactions
zz Methods of assessing and ensuring adherence to the treatment 
zz Methods for evaluating treatment response 
4.21 Name the drug(s) that may cause each of the following symptoms or 
adverse reactions.  
zz Nervous system damage: isoniazid
zz Hepatitis: isoniazid, pyrazinamide, rifampin
zz Eye damage: ethambutol
zz Orange discoloration of the urine: rifampin
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Answers to Study Questions (Continued)
4.22 How often should patients be monitored for adverse reactions  
to TB drugs?  
All patients should be seen by a clinician at least monthly during treatment 
and evaluated for possible adverse reactions. During this evaluation, clinicians 
should ask patients whether they have any of the symptoms that may be due to 
adverse reactions and examine patients for signs of possible adverse reactions. 
Also, public health workers who have regular contact with patients should ask 
patients about adverse reactions at every visit. 
4.23 Name four ways by which clinicians can assess whether a patient is 
adhering to treatment. 
zz Check to see whether the patient is reporting to the clinic as scheduled
zz Ask the patient to bring the prescribed medications to each clinic visit and 
count the number of pills to determine how many have been taken
zz Use special urine tests to detect the presence of the prescribed medication 
in the urine
zz Assess the patient’s clinical response to therapy
4.24 What is the best way to ensure that a patient adheres to treatment? 
The best way to ensure adherence to therapy is to use directly observed 
therapy (DOT). DOT means that a health care worker or another designated 
person watches the patient swallow each dose of the prescribed drugs. This 
method of treatment should be considered for all patients, because there is no 
way to predict reliably which patients will adhere to treatment. 
4.25 How can clinicians determine whether a patient is responding to 
treatment?  Select the correct answer(s).
A. Do bacteriologic evaluations 
B. Repeat tuberculin skin test 
C. Do clinical evaluations
D. Use special urine tests 
The correct answers are A and C. To determine whether a patient is responding 
to therapy, clinicians should do clinical evaluations and bacteriologic 
evaluations during therapy. Clinicians may also use x-rays to monitor a patient’s 
response to treatment, especially in patients who have negative culture results 
before treatment or who have certain types of extrapulmonary TB. 
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Answers to Study Questions (Continued)
4.26 Under what circumstances should patients be reevaluated?
Patients should be reevaluated promptly if their
zz Symptoms do not improve during the first 2 months of therapy
zz Symptoms worsen after improving initially
zz Culture results have not become negative after 2 months of treatment
zz Culture results become positive after being negative
zz Chest x-rays show worsening
4.27 What does reevaluating the patient mean?  
Reevaluating the patient means obtaining a new (sputum) specimen for TB culture 
and (if positive) for drug susceptibility testing, assessing whether the patient has 
been taking medication as prescribed, reviewing symptoms, performing a clinical 
evaluation, and repeating chest x-rays. 
4.28 What is the goal of TB case management?  
The goal of TB case management is to provide patient-centered care for completion 
of treatment and to ensure all public health activities related to stopping TB 
transmission are completed.
4.29 What should a public health worker do if he or she notices that a  
patient has symptoms of an adverse reaction?  
The public health worker should: 
zz Instruct the patient to stop the medication 
zz Report the situation to a clinician and arrange for a medical evaluation  
right away
zz Note the symptoms on the patient’s form
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4.1 You are sent to visit the home of a TB patient who was admitted 
to the hospital last week and diagnosed with infectious TB 
disease. Living in the home are his wife and his 1-year-old 
daughter. Neither one has symptoms of TB disease. You give 
them both a tuberculin skin test and return 2 days later to read 
the results. You find that the wife has 14 mm of induration, but 
the daughter has no induration.
z Should either one receive further evaluation for LTBI or TB 
disease? Should either one start LTBI treatment? Explain.
Yes, both should receive further evaluation for LTBI or TB disease. 
The wife is a contact of someone with infectious TB disease, and 
she has a positive skin test (greater than or equal to 5 mm for 
contacts). Therefore, after receiving a medical evaluation (to rule 
out TB disease, determine whether she has ever been treated for TB 
infection or disease, and identify any medical problems that may 
complicate therapy), she should complete an entire course of LTBI 
treatment, regardless of her age. 
The daughter is also a contact. Currently, she has a negative skin 
test. However, only 1 week has passed since she last spent time with 
her infectious father. It is possible that not enough time has passed 
for her to be able to react to the tuberculin skin test. At this point, it 
is impossible to determine whether she has TB infection. In addition, 
because she is a young child, she may develop TB disease very 
quickly after infection.
For these reasons, the daughter should start LTBI treatment now and 
be retested 8 to 10 weeks after she last spent time with her father. If 
she has a negative TST result on the repeat test, she may stop taking 
the medicine. If she has a positive TST result, she should complete 
an entire course of LTBI treatment.
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4.2 A 65-year-old man is prescribed LTBI treatment with isoniazid because 
he is a contact of a person with infectious TB disease and he has an 
induration of 20 mm to the tuberculin skin test. His baseline liver 
function tests are normal, but he drinks a six-pack of beer every day. 
z What kind of monitoring is necessary for this patient while he is 
taking isoniazid?
Even though his liver function tests are normal, this man is at high risk 
of isoniazid-associated hepatitis because he abuses alcohol and older 
persons are at higher risk for hepatitis. He should be educated about the 
symptoms of adverse reactions to isoniazid and be instructed to seek 
medical attention immediately if these symptoms occur. Furthermore, 
once a month, he should be seen by a clinician. The clinician should ask 
him about his symptoms, examine him for signs of adverse reactions, and 
consider performing liver function tests.
4.3 An 18-month-old girl is admitted to the hospital because of 
meningitis. Doctors discover that her grandmother had pulmonary 
TB disease and was treated with a 6-month regimen. The medical 
evaluation of the child confirms the diagnosis of TB meningitis. 
z For how long should the child be treated? Why?
The child should be treated for 9 to 12 months because she has TB 
meningitis.
4.4 You are assigned to deliver medications to TB patients as part of 
the DOT program where you work. When you visit Mr. Jackson’s 
house, you ask him how he is feeling. He tells you that he was up all 
night vomiting. 
z What are the possible causes? What should you do?
His vomiting may be a symptom of hepatitis (caused by isoniazid, 
rifampin, and pyrazinamide) or of stomach upset due to pyrazinamide. 
You should advise Mr. Jackson to stop his medication and report the 
situation to the clinician immediately. Mr. Jackson should receive a 
medical evaluation right away.
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4.5 Ms. Young, a patient who started treatment for TB disease last 
week, calls the TB clinic to complain that her urine has changed 
to an odd color. 
z Name two possible causes, and explain how each would 
affect the color of the urine.
One possible cause is the discoloration of body fluids, a common 
side effect of rifampin. This would cause Ms. Young’s urine to turn 
orange. The clinic nurse, physician, or public health worker should 
explain to Ms. Young that orange urine and other body fluids is a 
side effect of rifampin and that this is NOT a serious condition.
Another possible cause is hepatitis, which can be caused by 
isoniazid, rifampin, or pyrazinamide. Hepatitis, a serious condition, 
would cause Ms. Young’s urine to turn dark. If Ms. Young’s urine is 
dark, the situation should be reported to the clinician and Ms. Young 
should receive a medical examination right away.
4.6 Mr. Vigo was diagnosed with smear-positive pulmonary TB 
disease in January. He was treated with isoniazid, rifampin, and 
pyrazinamide by his private physician. He visited his physician 
again in March. His drug susceptibility test results were not 
available at the time of this appointment. Nevertheless, the 
physician discontinued his prescription of pyrazinamide and 
gave Mr. Vigo refills of isoniazid and rifampin. Mr. Vigo visited 
his physician again in April. He had a persistent cough, and his 
sputum smear was found to be positive.  
z What should be done next?
Mr. Vigo’s persistent cough and positive sputum smear indicate that 
he is not responding to therapy. The most likely explanations are: 
z He is not taking his medications as prescribed,
z He has drug-resistant TB and the regimen he has been 
prescribed is not adequate to treat his TB, or
z A combination of the two factors listed above.
The initial drug susceptibility test results should be located, 
and susceptibility tests should be repeated on a recent sputum 
specimen. In addition, his adherence should be evaluated, and he 
should be given DOT if possible.
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4.7 Ms. DeVonne began treatment for pulmonary TB disease 2 months 
ago, at the beginning of September. You have been supervising her 
eDOT. During the first few weeks of therapy, you noticed that Ms. 
DeVonne’s symptoms were improving a little. However, during an 
eDOT session in October, you see that Ms. DeVonne is coughing up 
blood, and she tells you that she feels like she has a fever. 
z What should you do?
Coughing up blood and feeling feverish are symptoms of TB disease. 
You should report Ms. DeVonne’s symptoms to the clinician and arrange 
for her to receive a medical evaluation right away. Also, you should note 
Ms. DeVonne’s symptoms on her form.
The fact that Ms. DeVonne’s TB symptoms got worse after improving 
initially indicates that she is not responding to therapy. Because she 
is receiving eDOT, Ms. DeVonne is probably taking her medications as 
prescribed. Therefore, the most likely explanation is that she has drug-
resistant TB and the prescribed regimen is not adequate to treat the TB.
Ms. DeVonne’s initial drug susceptibility test results should be located, and 
drug susceptibility tests should be repeated on a recent sputum specimen. 
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